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Background: The endocannabinoid system plays a key role in female reproduction, including implantation,
decidualization and placentation. In the present study, we aimed to analyze cannabinoid receptor 1 (CB1), CB2 and
fatty acid amid hydrolase (FAAH) expressions and localization in normal and preeclamptic placenta, in order to
determine whether placental endocannabinoid expression pattern differs between normal pregnancy and
preeclampsia.
Methods: Eighteen preeclamptic patients and 18 normotensive, healthy pregnant women with uncomplicated
pregnancies were involved in our case–control study. We determined CB1, CB2 and FAAH expressions by Western
blotting and immunohistochemistry in placental samples collected directly after Cesarean section.
Results: CB1 expression semi-quantified by Western blotting was significantly higher in preeclamptic placenta,
and these findings were confirmed by immunohistochemistry. CB1 immunoreactivity was markedly stronger in
syncytiotrophoblasts, the mesenchymal core, decidua, villous capillary endothelial and smooth muscle cells, as well
as in the amnion in preeclamptic samples compared to normal pregnancies. However, we did not find significant
differences between preeclamptic and normal placenta in terms of CB2 and FAAH expressions and immunoreactivity.
Conclusions: We observed markedly higher expression of CB1 protein in preeclamptic placental tissue. Increased CB1
expression might cause abnormal decidualization and impair trophoblast invasion, thus being involved in the
pathogenesis of preeclampsia. Nevertheless, we did not find significant differences between preeclamptic and normal
placental tissue regarding CB2 and FAAH expressions. While the detailed pathogenesis of preeclampsia is still unclear,
the endocannabinoid system could play a role in the development of the disease.
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Preeclampsia, characterized by hypertension and pro-
teinuria developing after the 20th week of gestation in a
previously normotensive woman, is a severe complica-
tion of human pregnancy with a worldwide incidence
of 3-8% [1]. It is among the leading causes of maternal,
as well as perinatal morbidity and mortality, even in
developed countries. Despite extensive research, the etio-
logy and pathogenesis of preeclampsia are not completely
understood. To our current knowledge, preeclampsia is
rather a syndrome than a single disease, originating either
from poorly developed placenta (placental preeclampsia)
or a maternal constitution described by abnormal systemic* Correspondence: molvarec@freemail.hu
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unless otherwise stated.inflammatory response based on microvascular dysfunc-
tion (maternal preeclampsia) [2,3]. The two-stage model
of placental preeclampsia consists from abnormal placen-
tal development (stage 1) due to insufficient trophoblast
invasion, where invasive extravillous cytotrophoblasts fail
to remodel the maternal spiral arteries in the placenta,
causing hypoxia and oxidative stress through impaired
uteroplacental circulation. Poor placentation between 6
to 18 weeks of gestation is followed by systemic mater-
nal symptoms, such as hypertension, proteinuria, clot-
ting and liver dysfunction caused by the increasingly
hypoxic placenta (stage 2) [4].
Endocannabinoids (ECs) are endogenous ligands bind-
ing to the similar receptor as delta-9-tetrahidrocannabinol
(Δ9-THC), the most potent psychotropic constituent of
marijuana. The G protein-coupled cannabinoid receptorsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ing pathways including adenylyl cyclase inhibiton leading
to diminished cyclic adenosine monophosphate (cAMP)
levels, activation of mitogen-activated protein kinases
(MAPK), and either activation or inhibition of various
ionic channels [5]. The most studied endogenous CB-
receptor ligand anandamide (AEA) is synthesized on
demand from the lipid precursor N-arachidonoyl phos-
phatidylethanolamine (NAPE) by a specific phospholip-
ase D enzyme (NAPE-PLD), and is primarily degraded
by fatty acid amid hydrolase (FAAH) to ethanolamine
and arachidonic acid. ECs are not stored, thus hydro-
lyzing enzymes play important role regulating extracel-
lular ligand levels [6].
AEA and CB1 are localized mainly in the central ner-
vous system, but also detected in the adrenal gland,
heart, uterus, testis and liver, whereas CB2 is primarily
restricted to immune and hematopoetic cells, and the
spleen [7]. This wide variety of localization implicates
that the endocannabinoid system (ECS) is responsible
for several pathophysiological processes: modulation of
ECS affects almost all human diseases such as obesity;
diabetes and diabetic complications; neurodegenerative,
inflammatory, cardiovascular, liver, gastrointestinal and
skin diseases; pain and psychiatric disorders; cachexia
and cancer amongst many others [8]. Regarding the fe-
male reproductive system, accumulating evidence shows
that CB-receptors, FAAH and ECs present in the ovary,
oviduct, uterus, embryo and placenta play a key role in fe-
male reproduction, including oogenesis, preimplantation
embryo development, oviductal embryo transport, im-
plantation, decidualization and placentation, pregnancy
maintenance and labor [5,9,10]. A recent study has shown
that tightly regulated EC levels are critical for female
reproductive success, as both silenced and elevated AEA
levels result in unidirectional gene expression changes,
causing impaired trophoblast migration ability [11]. Use of
marijuana during gestation results in fetal growth res-
triction, also suggesting the significance of the ECS in
pregnancy [12,13].
Given the role of the endocannabinoid system in im-
plantation, decidualization and placentation, in the pre-
sent study we aimed to analyze CB1, CB2 and FAAH
expressions and localization in normal and preeclamptic
placenta, in order to determine whether placental endo-




Eighteen preeclamptic patients and 18 normotensive,
healthy pregnant women with uncomplicated pregnan-
cies were involved in our case–control study. The study
participants were enrolled in the First Department ofObstetrics and Gynecology at the Semmelweis University,
Budapest, Hungary. All women were Caucasian and re-
sided in the same geographic area in Hungary. Exclusion
criteria were multifetal gestation, chronic hypertension,
diabetes mellitus, autoimmune disease, angiopathy, renal
disorder, maternal or fetal infection and fetal congenital
anomaly.
Preeclampsia was defined by increased blood pressure
(≥140 mmHg systolic or ≥90 mmHg diastolic on ≥2 occa-
sions at least 6 hours apart) that occurred after the 20th
week of gestation in a woman with previously normal
blood pressure, accompanied by proteinuria (≥0.3 g/24 h
or ≥1 + on dipstick in the absence of urinary tract in-
fection). Blood pressure returned to normal by the 12th
postpartum week in each preeclamptic study patient.
Preeclampsia was regarded as severe if any of the fol-
lowing criteria was present: blood pressure ≥160 mmHg
systolic or ≥110 mmHg diastolic, or proteinuria ≥5 g/24 h
(or ≥3 + on dipstick). Early onset of preeclampsia was
defined as onset of the disease before the 34th week of
gestation (between the 20th and 33rd completed gestatio-
nal weeks) [14]. Fetal growth restriction was diagnosed
if the fetal birth weight was below the 10th percentile for
gestational age and gender, based on Hungarian birth
weight percentiles.
The study protocol was approved by the Regional and
Institutional Committee of Science and Research Ethics
of the Semmelweis University, and written informed
consent was obtained from each patient. The study was
conducted in accordance with the Declaration of Helsinki.
Placental samples
Placental tissue samples were collected directly after
Cesarean section from a single site between the placental
rim and cord insertion, free of visible infarction and calci-
fication. The median gestational age was 38 weeks in the
control and 37 weeks in the preeclamptic group (Table 1).
One piece of the placental tissue sample was placed into a
plain tube without fixation, and stored at −80°C until the
measurements. A second piece of the sampled placental
tissue was fixed in 10% neutral-buffered formalin for 4
days before embedding in paraffin wax.
Western blot
The Western blot was performed on full-thickness blocks
from the chorionic plate to the basal plate in order to
determine the overall expression of CB1, CB2 and FAAH
in the placenta. One g of placental tissue was minced
well and homogenized in 10 ml of lysis buffer (20 mM
Tris–HCl, 5 mM EDTA, 10 mM EGTA, 2 mM DTT,
1 mM Na3VO4, 25 μg/ml PMSF, 2.5 μg/ml Leupeptin,
2.5 μg/ml Aprotinin, 625 μM sodium-pyrophosphate,
1 mM β-glycerophosphate, 0,1% Triton) by a homogenizer
for 3 × 15 sec. The homogenate was centrifuged at 800 g
Table 1 Clinical characteristics of healthy pregnant women and preeclamptic patients
Healthy pregnant women (n = 18) Preeclamptic patients (n = 18) Statistical significance (p value)
Age (years) 32 (28–35) 29 (28–32) NS
Pre-pregnancy BMI (kg/m2) 21.8 (18.7-26.4) 24.2 (21.2-29.6) NS
Smokers 1 (5.6%) 1 (5.6%) NS
Primiparas 6 (33.3%) 13 (72.2%) <0.05
Systolic blood pressure (mmHg) 120 (110–120) 180 (166–180) <0.001
Diastolic blood pressure (mmHg) 80 (70–80) 110 (100–110) <0.001
Gestational age at delivery (weeks) 38 (34–39) 37 (35–38) NS
Fetal birth weight (grams) 3100 (2300–3370) 2475 (1910–3400) NS
Fetal growth restriction 0 (0%) 4 (22.2%) NS
Data are presented as median (interquartile range) for continuous variables and as number (percentage) for categorical variables.
NS: Not significant; BMI: Body mass index.
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natant was collected and stored at −80°C and used within
four weeks for assays. To assess FAAH (AT1983a, mouse
monoclonal antibody, Abgent Inc., San Diego, CA, USA),
CB1 (EB06945 goat polyclonal anti-CB1 antibody, Everest
Biotech, England) and CB2 (EB06946 goat polyclonal anti-
CB2 antibody, Everest Biotech, England) expressions in
human placenta, 60 μg of extracted proteins were used for
Western blot analysis.
Samples were prepared in 2x Laemmli buffer contain-
ing 100 mM dithiothreitol and boiled in a water bath for
15 min. Protein (60 μg) was separated on a SDS-PAGE
(9 %) gel followed by a wet transfer to a nitrocellulose
membrane for 90 min. We used Ponceau S to determine
whether proteins migrated uniformly onto the nitrocel-
lulose membrane. After gently rinsing, the membranes
were blocked for 1 h at room temperature in 10% (wt/vol)
non-fat dried milk in Tris-buffered saline (TBS) with 0.1%
Tween 20 (TBST) and then incubated overnight with an-
tibody against the CB1 or CB2 or FAAH, respectively. The
antibodies were diluted (CB1 1:1000, CB2 and FAAH
1:500) in 1% bovine serum albumin in TBST. Blots were
incubated in a HRP-conjugated secondary antibody in
TBST for 1 h at room temperature and visualized by ECL-
Western blotting detection system (Amersham Pharmacia
Biotech, England). Mouse testicular homogenate and color
molecular weight markers were run parallel with the sam-
ples and were used to identify the specific bands. The
membrane was stripped at 60°C for 30 min in stripping
buffer (100 mM 2-mercaptoetanol, 2% SDS and 62.5 mM
Tris–HCl, pH 7.6), and were reprobed with MAPK1 anti-
body (1:1000) to normalize for loading.
Western blot signals were semi-quantified by densito-
metry analysis using a GELDOC 1.00-UV system (Biorad,
Hercules, CA, USA). The signals of the specific bands in
densitometry unit were adjusted according to the changes
of the corresponding density of MAPK1 bands on the
same loaded membrane. The deviation of the density of
MAPK1 bands from the mean was used to normalize thevalue of the CB1, CB2 or FAAH bands. The corrected sig-
nals of the preeclamptic placentas were expressed as % of
the mean values of normal placentas.
Immunohistochemistry (IHC)
Immunohistochemical staining was performed on 16
placental samples from each study group. Anti-CB1
(GTX100219) and anti-CB2 (GTX101357) rabbit poly-
clonal antibodies were obtained from GeneTex (Irvine,
CA, USA), whereas anti-FAAH (AT1983a) mouse mono-
clonal antibody was purchased from Abgent (San Diego,
CA, USA). In comparison to Western blot, different
CB-antibodies were chosen due to the incompatibility
of the antibodies used during Western blot with IHC
technology. Tissue sections (3 μm thick) were mounted
onto SuperFrost Ultra Plus Adhesion Slides (Thermo
Scientific, USA), dried in thermostat at 56°C for 1 h,
then 24 h at room temperature before use. Immuno-
staining process was carried out with Leica BOND-MAX
fully automated IHC & ISH system (Leica Biosystems,
St. Louis, MO, USA), using Bond Polimer Refine Detec-
tion kit (Leica Biosystems), which included peroxide
block (3% Hydrogen peroxide), post primary polymer
penetration enhancer (10% animal serum in Tris-buffer
saline and 0.09% ProClin™ 950), polymer Poly-HRP anti-
mouse/rabbit IgG (each at 8 μg/ml, containing 10% animal
serum in Tris-buffer saline and 0.09% ProClin™ 950), DAB
Part 1 (66 mM 3,3’-Diaminobenzidine tetrahydrochloride,
in stabilizer solution), DAB Part B (0.05% Hydrogen
Peroxide in a stabilizer solution) and Hematoxylin (0.02%).
Slides were dewaxed three times with Bond Dewax Solu-
tion (Leica Biosystems) at 72°C, then rehydrated in three
steps with graded alcohol and washed with buffer solution
(Bond Wash Solution, Leica Biosystems). Antigen retrieval
for CB1, CB2 and FAAH was performed by incubating
slides with Leica Bond Epitope Retrieval Solution 2
(pH 9.0) for 20 min. Primary antibodies diluted in Bond
Primary Antibody Diluent (Leica Biosystems) to 1:1000
for CB1 and CB2, and 1:1200 for FAAH were added for
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polimer for 15 min. After washing slides with buffer solu-
tion and deionized water, peroxidase activity was blocked
by incubation with peroxide block for 3 min. After add-
itional washing (buffer and deionized water), mixed DAB
refine was added to slides for 10 min, followed by de-
ionized washing for three times, and incubation with
Hematoxylin for 4 min. In between steps, sections were
washed with Leica Wash Solution 10x Concentrate
(diluted to 1:9 ratio). We used human cerebellum as
a positive control.
Images were taken on a Zeiss Axiolmager A2 micro-
scope equipped with an AxioCam ICc 1 camera (Carl
Zeiss Ltd., NY, USA) connected to a computer running
AxioVision image capture and processing software (version
release 4.8.2., Carl Zeiss Ltd.), captured at 200x and 400x
magnification.
Statistical analysis
The normality of continuous variables was assessed using
the Shapiro-Wilk’s W-test. As the continuous variables
were not normally distributed, non-parametric statistical
methods were applied. To compare continuous variables
between two groups, the Mann–Whitney U-test was used.
The Fisher exact and Pearson χ2 tests were performed to
compare categorical variables between groups.
Statistical analyses were carried out using the following
software: STATISTICA (version 11; StatSoft, Inc., Tulsa,Figure 1 Representative Western blotting demonstrating CB1 (A), CB2
placental tissue.Oklahoma, USA) and Statistical Package for the Social
Sciences (version 22 for Windows; SPSS, Inc., Chicago,
Illinois, USA). For all statistical analyses, p < 0.05 was con-
sidered statistically significant.
In the article, data are reported as median (interquar-
tile range) for continuous variables and as number (per-
centage) for categorical variables.
Results
Patient characteristics
The clinical characteristics of the study participants are
presented in Table 1. There were no statistically significant
differences in terms of maternal age, pre-pregnancy body
mass index (BMI), gestational age at delivery and fetal birth
weight and the percentage of smokers between the two
study groups. The systolic and diastolic blood pressures, as
well as the percentage of primiparas, were significantly
higher in the preeclamptic group than in the control group.
Fetal growth restriction was absent in healthy pregnant
women, whereas it occurred in 4 cases in the preeclamptic
group. Fourteen women had severe preeclampsia and 5
patients experienced early onset of the disease.
Western blot
Representative Western blotting of CB1, CB2 and FAAH
expressions in normal and preeclamptic placental tissue
is shown in Figure 1. According to densitometry analysis,
placental expression of CB1 protein was significantly(B) and FAAH (C) expressions in normal and preeclamptic
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healthy pregnant women (149.3 (105.0-279.7) % versus
98.1 (67.3-131.0) %, p = 0.008; Figure 2A). Nevertheless,
no significant differences were observed in placental
CB2 (105.5 (80.9-133.2) % versus 65.8 (45.5-128.4) %,
p > 0.05; Figure 2B) and FAAH (112.2 (94.7-143.8) %
versus 91.2 (63.3-128.4) %, p > 0.05; Figure 2C) protein
expressions between the two study groups.
Immunohistochemistry
CB1 immunoreactive staining patterns
Strong CB1 immunoreactivity was detected in the syncy-
tiotrophoblast layer, as well as in the endothelial cells of
blood vessels. Less intense, but positive staining was found
in the decidua, capillary smooth muscle cells, stromal fi-
broblasts and in the amnion. CB1 immunoreactivity in the
previously mentioned localizations was observed both in
normal and preeclamptic placenta, however, staining was
markedly more intense in preeclampsia (Figure 3A-E).
CB2 immunoreactive staining patterns
Immunoreactive CB2 was detected both in normal and
preeclamptic placenta, but there was no difference in the
staining intensity and localization between the two groups.
Syncytiotrophoblasts and stromal fibroblasts showed posi-
tive reaction for CB2, although staining was less strong
compared to CB1. CB2 immunoreactivity was absent in
blood vessels, but detectable in the decidua. We found
CB2 immunoreactivity in spot-like distribution in the
amnion (Figure 3F-H).
FAAH immunoreactive staining patterns
FAAH immunoreactivity showed similar localization to
CB2, as we found positive reaction in syncytiotropho-
blasts and stromal fibroblasts (however, staining inten-
sity was reduced compared to CB1 immunoreactivity).
Immunoreactive FAAH was absent in blood vessels, but
detectable in the decidua and less markedly in spot-
like distribution in the amnion. FAAH immunoreactiveFigure 2 Densitometry analysis of CB1 (p = 0.008, A), CB2 (p > 0.05, B
placental tissue. Middle line: median; Box: interquartile range (25–75 percstaining intensity and localization was similar in normal
and preeclamptic placenta (Figure 3I-K).
Discussion
In this study, we determined CB1, CB2 and FAAH expres-
sions in placental samples from healthy and preeclamptic
women. According to our findings, CB1 expression mea-
sured by Western blotting was markedly stronger in pre-
eclamptic placenta, and these findings were confirmed by
strong CB1 immunoreactivity in various placental localiza-
tions. However, we did not find significant differences be-
tween preeclamptic and normal placenta in terms of CB2
and FAAH expressions and immunoreactivity.
In both normal and preeclamptic placenta, immunore-
active CB1, CB2 and FAAH were detected in syncytiotro-
phoblasts, the mesenchymal core and decidua. We found
strong CB1 immunoreactivity in endothelial cells of blood
vessels and moderate reaction in vascular smooth muscle
cells, whereas CB2 and FAAH immunoreactivity was ab-
sent in these localizations. Regarding the chorionic plate, a
less intensive CB1 immunoreactivity and spot-like positive
CB2 and FAAH staining was observed in the amnion. Our
findings were similar to the literature published earlier re-
garding ECS localization in human placenta [15-18].
Our results have demonstrated that CB1 expression
and immunoreactivity was markedly higher in syncytio-
trophoblasts and the mesenchymal core in preeclamptic
samples compared to normal pregnancies. This is con-
sistent with earlier reports, where strong immunoposi-
tivity for CB1 was found in trophoblast cells of placental
samples of spontaneous miscarriage, although we did
not detect lower FAAH signal in syncytiotrophoblasts
as formerly reported [18]. These findings can be explained
by the role of ECS in implantation and placental develop-
ment. In rat pregnancy, major endocannabinoid levels in-
crease gradually during pregnancy, while FAAH activity
maintained constant during placentation [19]. As FAAH
is responsible for protecting the fetus and placenta
from high AEA levels [9], an early increase in AEA
levels caused by higher NAPE-PLD activity can lead to) and FAAH (p > 0.05, C) expressions in normal and preeclamptic
entile); Whisker: range (excluding outliers).
Figure 3 Localization of CB1, CB2 and FAAH in human placental villi, decidua and cerebellum. CB1 specific staining is shown in normal
(A) and preeclamptic (B) placental tissues, images were captured at 200× magnification. Further images demonstrate strong CB1 positivity in
preeclamptic placental villi (D) and decidua (E) at 400× magnification. Arrow indicates strong CB1 immunoreactivity in villous capillary endothelial
cells. Positive control reaction for CB1 is revealed in human cerebellum (C). CB2 specific staining is shown in normal (F) and preeclamptic
(G) placental tissues, and in human cerebellum (H) as a positive control. FAAH specific staining is presented in normal (I) and preeclamptic
(J) placental tissues, and in human cerebellum (K) as a positive control. Negative controls are shown in human placental villi and decidua (L), and
in human cerebellum (M). Placental tissue samples from normal pregnancy and preeclampsia were captured at 200× magnification, while
positive and negative controls were taken at 400× magnification; bar =100 μm.
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blast cell differentiation and invasion [20]. Trophoblast
cells are responsible to invade the maternal decidua and
forming the placenta. The tightly regulated invasion is af-
fected by ECs, where both over- and underexpression of
CB1 causes impaired trophoblast migration capabilities
[11]. We hypothesize that high CB1 expression can result
in poor placentation through insufficient trophoblast inva-
sion, thereby leading to preeclampsia.
We also observed high CB1 expression and immuno-
reactivity in preeclamptic decidua. Earlier studies have
shown that synthetic cannabinoids inhibit human decid-
ual cell differentiation and mediate apoptosis through
cAMP-dependent mechanism via CB1 activation [21].Exposed cells expressed less decidualization-specific mar-
kers (such as prolactin, laminin and IGFBP-1) and showed
significant cAMP level reduction, which led to morpho-
logical changes in decidual fibroblasts with DNA fragmen-
tation. Therefore, elevated CB1 expression can result in
increased apoptosis, thus impeding decidua establishment.
However, it is also possible that the overexpression of CB1
exerts its effect mostly by disturbing decidua remodeling,
thereby compromising placentation, leading to sponta-
neous abortion and preeclampsia.
Interestingly, according to the immunohistochemistry,
preeclamptic placental samples also showed higher CB1
immunoreactivity in villous capillary endothelial and
smooth muscle cells compared to normal pregnancy. This
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ECs can cause vasodilation through CB1, TRPV1 and
NO-mediated or NO-independent mechanisms [22], thus
enhancing the blood supply of the placenta. AEA exerts
its vasorelaxant effect on endothelial cells in various ways,
such as by upregulating the expression and activity of the
inducible NO synthase (NO-mediated pathway) [23]. In
the cerebral circulation, CB1 also has vasodilatory effects
directly on vascular smooth muscle by inhibiting calcium
entry through L-type calcium channels [24].
Abán et al. recently measured CB1 and FAAH expres-
sions and localization in healthy and preeclamptic pla-
centa [25]. They detected similar CB1 protein expression
in both normal and preeclamptic tissues; however, NAPE-
PLD expression was significantly enhanced, while FAAH
was lower or undetectable in preeclampsia. These findings
confirm the pathological activation of the ECS in pre-
eclampsia, although the study does not report on decidual
expression, as well as on expression and localization of
CB2 protein. Differences between the latter and our re-
sults can be explained by the differences in gestational
weeks of the preeclamptic group, in the severity of the dis-
ease or in antibodies used.
A limitation of our study is the lack of measurement
of placental anandamide levels and NAPE-PLD expres-
sion. Furthermore, our study had a case–control design,
thus direct causation cannot be determined. Neverthe-
less, abnormal placentation occurs in the first half of
pregnancy, while the clinical syndrome only appears in
the second, which rules out prospective studies on the
placenta. It is also possible that increased CB1 expression
is rather a consequence than a cause of preeclampsia,
however there are no data in the literature demonstrating
association between placental CB1 expression levels and
PE risk factors or pathophysiological signals. Experimental
studies are required to determine the causative role of in-
creased placental expression of cannabinoid receptor 1 in
preeclampsia.Conclusions
We observed markedly higher expression of CB1 protein
in preeclamptic placental tissue. Increased CB1 expres-
sion might cause abnormal decidualization and impair
trophoblast invasion, thus being involved in the patho-
genesis of preeclampsia. Nevertheless, we did not find
significant differences between preeclamptic and normal
placental tissue regarding CB2 and FAAH expressions.
While the detailed pathogenesis of preeclampsia is still
unclear, the endocannabinoid system could play a role in
the development of the disease.Competing interests
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